Veterinary Oncology Market Report 2025

This Veterinary Oncology market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The veterinary oncology market size has grown rapidly in recent years. It will grow from $0.4 billion in 2024 to $0.45 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increasing pet ownership, humanization of pets, knowledge transfer from human oncology, increasing awareness of pet health, and pharmaceutical developments.

The veterinary oncology market size is expected to see rapid growth in the next few years. It will grow to $0.69 billion in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to personalized medicine for animals, rising prevalence of cancer in animals, growing geriatric pet population, expanded access to specialized care, regulatory support and approvals. Major trends in the forecast period include advanced diagnostic technologies, personalized treatment approaches, immunotherapy advancements, targeted therapies, telemedicine in oncology consultations.

The rising prevalence of cancer in pets is anticipated to significantly drive the growth of the veterinary oncology market in the future. Cancer is a condition characterized by uncontrolled cell growth that can spread to other parts of the body, and in pets, it often presents as physical symptoms like tumors or swelling. Veterinary oncology focuses on diagnosing and treating cancer in animals, aiming to reduce metastasis and the spread of the disease. Consequently, an increase in pet cancer cases is expected to elevate the demand for veterinary oncology services. For instance, according to the Cancer Letter, a US-based publication dedicated to cancer research, an estimated 6 million pet dogs will be diagnosed with cancer in the United States in 2024. Additionally, data from the British Small Animal Veterinary Association (BSAVA), a UK-based veterinary organization, indicated in November 2023 that approximately 1 in 4 dogs and 1 in 5 cats will be diagnosed with cancer during their lifetime. Thus, the increasing prevalence of cancer in pets is driving the veterinary oncology market forward.

The increasing adoption of pets is projected to significantly boost the veterinary oncology market in the coming years. Pet adoption involves legally bringing an animal into one’s home and providing care, shelter, and companionship. Pet owners, motivated by a dedication to their pets’ health and well-being, are more inclined to pursue preventive healthcare and medical treatments, including cancer diagnostics and therapies. For example, according to the UK Pet Food Organization, a UK-based entity, there are 13.5 million dogs and 12.5 million cats in the UK in 2024, representing an increase of 1.5 million for each species. Therefore, the growing trend of pet adoption is contributing to the expansion of the veterinary oncology market.

Leading companies in the veterinary oncology market are concentrating on developing neoantigens, which are unique tumor-specific antigens resulting from mutations in cancer cells. Neoantigens are distinct protein fragments produced by tumor-specific mutations, differentiating them from normal antigens found in healthy tissues. These proteins arise from genetic alterations (mutations) in the tumor's DNA. For example, in October 2024, a US-based biotechnology company launched a cancer vaccine trial for dogs. The exploration of neoantigens is central to the development of cancer vaccines and other forms of immunotherapy, aiming to enhance the immune response specifically against cancer cells while minimizing the impact on normal cells.

Major players are strategically forging partnerships and collaborations with startups and mid-sized entities in the veterinary oncology market to diversify their offerings. These alliances serve as catalysts for portfolio expansion and geographical outreach. A pertinent example is the strategic partnership between Thrive Pet Healthcare and FidoCure initiated in June 2022. This collaboration endeavors to redefine veterinary cancer care by leveraging FidoCure's cutting-edge precision medicine platform and diagnostic algorithms across Thrive Pet Healthcare's extensive network of over 350 veterinary care clinics, aiming to enhance outcomes for pets diagnosed with cancer.

In July 2022, Zomedica Corp., a veterinary health company based in the US specializing in diagnostic and therapeutic products, completed the acquisition of Assisi Animal Health LLC for an undisclosed sum. This strategic acquisition aims to synergize resources between Zomedica and Assisi, empowering Zomedica to fortify and broaden its product offerings, ultimately providing advanced solutions to elevate companion animal care. Assisi Animal Health LLC, also based in the US, focuses on offering drug-free devices utilizing targeted pulsed electromagnetic field (tPEMF) technology, specifically used for reducing inflammation and treating cancer in dogs.

Veterinary oncology involves the specialized diagnosis and treatment of cancer in animals, aiming to integrate cancer therapies while maintaining the overall quality of life for the affected animals. This field focuses on providing cancer medicine and treatment services tailored to the unique needs of animals.

The primary types of therapies in veterinary oncology include surgery, radiology, chemotherapy, and other specialized treatments. Surgery involves procedures to either remove or repair affected body parts or to assess the presence of disease. A diverse range of animals, including equines, canines, felines, and other species, are involved in veterinary oncology. The field encompasses various cancer types such as lymphomas, mast cell cancer, mammary cancer, squamous cell cancer, among others, specific to different animal species.

The veterinary oncology market research report is one of a series of new reports that provides veterinary oncology market statistics, including veterinary oncology industry global market size, regional shares, competitors with veterinary oncology market share, detailed veterinary oncology market segments, market trends, and opportunities, and any further data you may need to thrive in the veterinary oncology industry. This veterinary oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the veterinary oncology market include PetCure Oncology Inc., Zoetis Inc., Karyopharm Therapeutics Inc., Varian Medical Systems Inc., Accuray Incorporated, Boehringer Ingelheim International GmbH, Elanco Animal Health Inc., One Health Company Inc., Regeneus Limited, VetDC Inc., Pharmaust Limited, AdvaVet Inc., Nippon Zenyaku Kogyo Company Limited, Rhizen Pharmaceutical SA, AB Science SAS, Pfizer Inc., Takis Biotech GmbH, Qbiotics LLC, Jaguar Animal Health Solutions Inc., Orion Corporation A/B, Invectys S.A., Virbac SA, SeQuent Scientific Limited, Ceva Santé Animale S.A., Vetoquinol S.A., IDVet Inc., Bayer Aktiengesellschaft, Morphogenesis Inc., ZENOAQ GmbH, Oncovet Clinical Research Inc.

Asia-Pacific was the largest region in the veterinary oncology market in 2024. North America is expected to be the fastest-growing region in the veterinary oncology market report during the forecast period. The regions covered in the veterinary oncology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The veterinary oncology market includes revenues earned by entities by providing cryosurgery, comprehensive care, immunotherapy, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.